Logo image of IMAB

I-MAB-SPONSORED ADR (IMAB) Stock Fundamental Analysis

NASDAQ:IMAB - Nasdaq - US44975P1030 - ADR - Currency: USD

0.9567  -0.01 (-1.37%)

Fundamental Rating

2

Taking everything into account, IMAB scores 2 out of 10 in our fundamental rating. IMAB was compared to 571 industry peers in the Biotechnology industry. IMAB has a bad profitability rating. Also its financial health evaluation is rather negative. IMAB is valied quite expensively at the moment, while it does show a decent growth rate.


Dividend Valuation Growth Profitability Health

Quickly go to:

1

1. Profitability

1.1 Basic Checks

IMAB had negative earnings in the past year.
IMAB had negative earnings in 4 of the past 5 years.
IMAB had negative operating cash flow in 4 of the past 5 years.
IMAB Yearly Net Income VS EBIT VS OCF VS FCFIMAB Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2017 2018 2019 2020 2021 2022 2023 0 -500M -1B -1.5B -2B -2.5B

1.2 Ratios

IMAB has a Return On Assets (-56.09%) which is in line with its industry peers.
IMAB has a Return On Equity (-85.31%) which is comparable to the rest of the industry.
Industry RankSector Rank
ROA -56.09%
ROE -85.31%
ROIC N/A
ROA(3y)-53.09%
ROA(5y)-47.46%
ROE(3y)-74.2%
ROE(5y)-70.62%
ROIC(3y)N/A
ROIC(5y)N/A
IMAB Yearly ROA, ROE, ROICIMAB Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2017 2018 2019 2020 2021 2022 2023 0 -50 -100

1.3 Margins

Looking at the Gross Margin, with a value of 100.00%, IMAB belongs to the top of the industry, outperforming 99.11% of the companies in the same industry.
The Profit Margin and Operating Margin are not available for IMAB so they could not be analyzed.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM 100%
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
IMAB Yearly Profit, Operating, Gross MarginsIMAB Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2017 2018 2019 2020 2021 2022 2023 0 -2K -4K

More info and screens

3

2. Health

2.1 Basic Checks

IMAB does not have a ROIC to compare to the WACC, probably because it is not profitable.
Compared to 1 year ago, IMAB has less shares outstanding
The number of shares outstanding for IMAB has been increased compared to 5 years ago.
IMAB has a worse debt/assets ratio than last year.
IMAB Yearly Shares OutstandingIMAB Yearly Shares OutstandingYearly Shares Outstanding 2017 2018 2019 2020 2021 2022 2023 20M 40M 60M
IMAB Yearly Total Debt VS Total AssetsIMAB Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2017 2018 2019 2020 2021 2022 2023 2B 4B 6B

2.2 Solvency

Based on the Altman-Z score of -5.08, we must say that IMAB is in the distress zone and has some risk of bankruptcy.
The Altman-Z score of IMAB (-5.08) is worse than 62.39% of its industry peers.
IMAB has a Debt/Equity ratio of 0.02. This is a healthy value indicating a solid balance between debt and equity.
The Debt to Equity ratio of IMAB (0.02) is comparable to the rest of the industry.
Industry RankSector Rank
Debt/Equity 0.02
Debt/FCF N/A
Altman-Z -5.08
ROIC/WACCN/A
WACC9.34%
IMAB Yearly LT Debt VS Equity VS FCFIMAB Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2017 2018 2019 2020 2021 2022 2023 0 2B 4B

2.3 Liquidity

A Current Ratio of 5.67 indicates that IMAB has no problem at all paying its short term obligations.
Looking at the Current ratio, with a value of 5.67, IMAB is in line with its industry, outperforming 59.54% of the companies in the same industry.
IMAB has a Quick Ratio of 5.67. This indicates that IMAB is financially healthy and has no problem in meeting its short term obligations.
IMAB has a Quick ratio (5.67) which is in line with its industry peers.
Industry RankSector Rank
Current Ratio 5.67
Quick Ratio 5.67
IMAB Yearly Current Assets VS Current LiabilitesIMAB Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2017 2018 2019 2020 2021 2022 2023 1B 2B 3B 4B 5B

More info and screens

4

3. Growth

3.1 Past

The Earnings Per Share has grown by an impressive 45.59% over the past year.
Looking at the last year, IMAB shows a very strong growth in Revenue. The Revenue has grown by 112.47%.
IMAB shows a very negative growth in Revenue. Measured over the last years, the Revenue has been decreasing by -12.47% yearly.
EPS 1Y (TTM)45.59%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%6.13%
Revenue 1Y (TTM)112.47%
Revenue growth 3Y-73.83%
Revenue growth 5Y-12.47%
Sales Q2Q%110.11%

3.2 Future

Based on estimates for the next years, IMAB will show a very negative growth in Earnings Per Share. The EPS will decrease by -19.08% on average per year.
IMAB is expected to show a strong growth in Revenue. In the coming years, the Revenue will grow by 32.77% yearly.
EPS Next Y92.19%
EPS Next 2Y31.06%
EPS Next 3Y22.09%
EPS Next 5Y-19.08%
Revenue Next Year-100%
Revenue Next 2Y-41.42%
Revenue Next 3Y-25.99%
Revenue Next 5Y32.77%

3.3 Evolution

When comparing the Revenue growth rate of the last years to the growth rate of the upcoming years, we see that the growth is accelerating.
IMAB Yearly Revenue VS EstimatesIMAB Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2017 2018 2019 2020 2021 2022 2023 2024 2025 2026 2027 2028 2029 2030 2031 2032 0 500M 1B 1.5B
IMAB Yearly EPS VS EstimatesIMAB Yearly EPS VS EstimatesYearly EPS VS Estimates 2017 2018 2019 2020 2021 2022 2023 2024 2025 2026 2027 2028 2029 2030 2031 2032 0 10 20

More info and screens

1

4. Valuation

4.1 Price/Earnings Ratio

The Price/Earnings Ratio is negative for IMAB. In the last year negative earnings were reported.
Besides the negative Price/Earnings Ratio, also the Forward Price/Earnings Ratio is negative for IMAB. No positive earnings are expected for the next year.
Industry RankSector Rank
PE N/A
Fwd PE N/A
IMAB Price Earnings VS Forward Price EarningsIMAB Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 20 40 60 80

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
IMAB Per share dataIMAB EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 10 -10 20

4.3 Compensation for Growth

IMAB's earnings are expected to grow with 22.09% in the coming years. This may justify a more expensive valuation.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y31.06%
EPS Next 3Y22.09%

More info and screens

0

5. Dividend

5.1 Amount

No dividends for IMAB!.
Industry RankSector Rank
Dividend Yield N/A

More info and screens

I-MAB-SPONSORED ADR

NASDAQ:IMAB (2/24/2025, 3:31:47 PM)

0.9567

-0.01 (-1.37%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)11-14 2024-11-14/bmo
Earnings (Next)03-13 2025-03-13/amc
Inst Owners15.29%
Inst Owner Change-99.99%
Ins Owners0.67%
Ins Owner ChangeN/A
Market Cap77.38M
Analysts84.44
Price Target5.78 (504.16%)
Short Float %3.13%
Short Ratio1.73
Dividend
Industry RankSector Rank
Dividend Yield N/A
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)N/A
Avg EPS beat(2)N/A
Min EPS beat(2)N/A
Max EPS beat(2)N/A
EPS beat(4)N/A
Avg EPS beat(4)N/A
Min EPS beat(4)N/A
Max EPS beat(4)N/A
EPS beat(8)N/A
Avg EPS beat(8)N/A
EPS beat(12)N/A
Avg EPS beat(12)N/A
EPS beat(16)N/A
Avg EPS beat(16)N/A
Revenue beat(2)N/A
Avg Revenue beat(2)N/A
Min Revenue beat(2)N/A
Max Revenue beat(2)N/A
Revenue beat(4)N/A
Avg Revenue beat(4)N/A
Min Revenue beat(4)N/A
Max Revenue beat(4)N/A
Revenue beat(8)N/A
Avg Revenue beat(8)N/A
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)-10.53%
PT rev (3m)-16.05%
EPS NQ rev (1m)0%
EPS NQ rev (3m)0%
EPS NY rev (1m)93.58%
EPS NY rev (3m)94.62%
Revenue NQ rev (1m)N/A
Revenue NQ rev (3m)N/A
Revenue NY rev (1m)N/A
Revenue NY rev (3m)N/A
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S 2.8
P/FCF N/A
P/OCF N/A
P/B 0.05
P/tB 0.05
EV/EBITDA N/A
EPS(TTM)-18.12
EYN/A
EPS(NY)-0.13
Fwd EYN/A
FCF(TTM)N/A
FCFYN/A
OCF(TTM)N/A
OCFYN/A
SpS0.34
BVpS21.24
TBVpS19.78
PEG (NY)N/A
PEG (5Y)N/A
Profitability
Industry RankSector Rank
ROA -56.09%
ROE -85.31%
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM 100%
FCFM N/A
ROA(3y)-53.09%
ROA(5y)-47.46%
ROE(3y)-74.2%
ROE(5y)-70.62%
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexcg growth 3YN/A
ROICexcg growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
F-ScoreN/A
Asset Turnover0.01
Health
Industry RankSector Rank
Debt/Equity 0.02
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr N/A
Cap/Sales N/A
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 5.67
Quick Ratio 5.67
Altman-Z -5.08
F-ScoreN/A
WACC9.34%
ROIC/WACCN/A
Cap/Depr(3y)N/A
Cap/Depr(5y)N/A
Cap/Sales(3y)N/A
Cap/Sales(5y)N/A
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)45.59%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%6.13%
EPS Next Y92.19%
EPS Next 2Y31.06%
EPS Next 3Y22.09%
EPS Next 5Y-19.08%
Revenue 1Y (TTM)112.47%
Revenue growth 3Y-73.83%
Revenue growth 5Y-12.47%
Sales Q2Q%110.11%
Revenue Next Year-100%
Revenue Next 2Y-41.42%
Revenue Next 3Y-25.99%
Revenue Next 5Y32.77%
EBIT growth 1Y37.24%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year-671.97%
EBIT Next 3Y-30.31%
EBIT Next 5Y35.29%
FCF growth 1YN/A
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1YN/A
OCF growth 3YN/A
OCF growth 5YN/A